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Abstract
Background
Buruli ulcer is a chronic ulcerating skin condition, with the highest burden found in Central
and West Africa where it disproportionately affects the most vulnerable populations. Treat-
ment is demanding, comprising eight-weeks of daily antibiotics, regular wound care and
possible surgical intervention. Treatment completion is key to optimising outcomes, how-
ever the degree of and barriers to this are not well understood. Recent change from
injectable treatment (SR8) to oral treatment (CR8) has made it feasible to further decentra-
lise care, potentially improving treatment access and completion. However, the impact of
this and of other demographic and clinical influences on treatment completion must be
explored first to ensure appropriate models of care are developed.
Methodology/Principal findings
A retrospective clinical notes review and secondary data analysis of records from patients
diagnosed between 1 January 2006–31 December 2018 at four district hospital clinics in the
Ashanti and Central Regions, Ghana. Univariable analyses and multivariable logistic regres-
sion were performed to assess the association between explanatory variables and treat-
ment completion.
There were 931 patient episodes across the four clinics with overall treatment completion
of 84.4%. CR8 was associated with higher treatment completion compared to SR8 (OR 4.1,
P = 0.001). There was no statistically significant association found between distance from
patient residence to clinic and treatment completion.
Conclusions/Significance
Improved treatment completion with CR8 supports its use as first line therapy and may
enable decentralisation to fully community-based care. We did not find an association
between distance to care and treatment completion, though analyses were limited by data
availability. However, we did find evidence that distance to care continues to be associated
with more severe forms of disease, which may reflect the higher costs of accessing care
PLOS NEGLECTED TROPICAL DISEASES
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008369 May 26, 2020 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Collinson S, Frimpong VNB, Agbavor B,
Montgomery B, Oppong M, Frimpong M, et al.
(2020) Barriers to Buruli ulcer treatment
completion in the Ashanti and Central Regions,
Ghana. PLoS Negl Trop Dis 14(5): e0008369.
https://doi.org/10.1371/journal.pntd.0008369
Editor: Daniel Patrick O’Brien, Barwon Health,
AUSTRALIA
Received: January 23, 2020
Accepted: May 6, 2020
Published: May 26, 2020
Copyright: © 2020 Collinson et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have declared
that no competing interests exist.
and lower awareness of the condition the further a patient lives. Decentralised care must
therefore also continue to support community engagement and active outreach to identify
cases early.
Author summary
Buruli ulcer (BU) is a chronic ulcerating tropical skin disease known to particularly affect
vulnerable populations. Without early detection and effective treatment it can lead to dis-
figurement, disability and stigma. In order to improve outcomes, we need to understand
what factors prevent patients from accessing and completing treatment, however these
factors are often not well understood. Factors considered to potentially affect treatment
completion include access to care and type of treatment. In this study we analysed data
available from clinical records of patients treated in Ghana to identify whether type of
treatment and common patient characteristics were associated with treatment comple-
tion. We found that treatment completion was higher in patients who took a newly intro-
duced oral treatment compared to those who took the traditional injectable treatment.
We did not find a difference in treatment completion between patients living close to the
clinic and those living further away, however we found that those living further were
more likely to present with more advanced disease. The results from this study suggest
that management for patients living far from care needs to be improved. The newly rec-
ommended oral treatment makes it feasible to provide care away from health centres and
the improved treatment completion seen in this study supports its use. However, further
research should be conducted to determine how fully community based care can best be
provided.
Introduction
Buruli ulcer (BU) is a chronic, ulcerating skin condition resulting from infection with Myco-
bacterium ulcerans [1]. Classified as a neglected tropical disease (NTD), it disproportionately
affects some of the world’s poorest populations [2]. The distribution of BU is geographically
focal [3] and whilst it is known to be prevalent in 33 countries, including parts of Asia, South
America and the Western Pacific, the highest burden is in Central and West Africa [1]. In
Ghana, BU is one of the most common skin NTDs [4], and in 2018 it had the highest number
of reported cases globally [5], though this may be due, in part, to efforts to improve early case
detection [6]. Despite this, BU is known to be considerably underreported across endemic
countries, owing to factors including the stigma surrounding skin conditions, logistical and
financial difficulties accessing care and problems with recognition and diagnosis of the condi-
tion [3]. Clinical manifestations range from small nodules, plaques or ulcers to larger lesions
which can extend to the bone or affect critical sites including the head and genitalia [7]. With
the potential to cause severe long-term morbidity, prompt and effective management is essen-
tial [8].
Completion of BU treatment is deemed necessary in order to ensure adequate wound heal-
ing and prevent recurrence [7,9], however the degree and characteristics of BU treatment com-
pletion in West Africa have not been extensively researched. A study in Ghana suggested that
treatment was only fully completed in 46% of cases between 2008–2012 [10] but other studies
have reported much higher rates of treatment completion in the region of 94–98% [11,12].
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Given such wide discrepancies further work is needed to understand factors associated with
adherence and successful BU treatment completion.
Possible barriers to treatment completion have included adverse effects of the treatment
itself and the direct and indirect costs and accessibility of care. Until recently, patients required
eight weeks of daily antibiotics with rifampicin and the injectable streptomycin (SR8) [7]. Both
pain from injections and the toxicity of streptomycin, with its risks of hearing loss and renal
impairment, have been regarded as key issues affecting the management of BU [13,14].
Recently, a fully oral regimen of clarithromycin and rifampicin (CR8) has been proven equally
efficacious and is now recommended by WHO [1,15,16]. Financial and logistical difficulties in
accessing care have also been implicated as key factors determining treatment completion
[10,13]. An economic analysis of the cost of outpatient care for BU in Ghana indicated the
potential for it to place catastrophic financial demands on patients: the total household costs of
treating one case, including the costs required for transportation to access care and the indirect
costs arising from productivity loss were found to constitute almost half of the annual house-
hold income [17]. Recent studies indicate that whilst health education has helped improve
understanding of the condition in Ghana, many patients will still seek local herbal treatment
due to concerns regarding the costs of transportation and the accessibility of BU clinics [18].
With the issues of cost and accessibility of care delaying or preventing appropriate care seek-
ing, it is feasible that they may also affect treatment completion. The new fully oral treatment
regimen may improve treatment adherence both through increased tolerability compared to
the injectable regimen but also because it reduces the need for healthcare facility visits to
receive daily injections and is therefore associated with reduced indirect patient costs.
A number of mechanisms to support treatment completion have been suggested and are
particularly aimed at overcoming logistical and financial barriers patients face. Provision of
free transportation to clinics, reducing both the direct transportation costs and, with its
increased convenience, the opportunity costs of spending time away from employment or
school, has been suggested [19]. The notion of bringing care closer to patients has also been
proposed and is supported by the improved treatment retention and increased likelihood of
treatment success seen through decentralisation of care in conditions such as tuberculosis
(TB) and HIV [20–23]. There has been increasing decentralisation of care for BU. Whilst sur-
gery used to be the mainstay of management, the introduction of an antibiotic regimen in
2004 [24] has meant that now only more extensive BU lesions require surgical management
[7]. Furthermore, with the introduction of the oral antibiotic regimen patients do not need to
see a health worker daily to receive antibiotic injections, but rather at less frequent intervals to
collect a supply of oral antibiotics [10,25]. Whilst patients still require regular, often daily,
wound care [1], a study in Benin showed that if this can be provided locally, less severe lesions
can be fully treated in the community, thus reducing the fear and costs associated with attend-
ing BU clinics [21]. Community-based treatment of BU is also likely to be mutually supportive
of current activities aimed at early case-detection: it is likely to support the use of community-
based volunteers to increase awareness and early referral of cases to BU facilities [20] and by
diagnosing BU at an early stage, cases will be more amenable to community-based
management.
There are concerns that moving to a fully community-based model and thereby removing
any direct observation of therapy (DOT) could reduce treatment completion [10]. The use of
DOT for similarly demanding treatment schedules, such as TB management, has shown some
positive results; a recent meta-analysis found that DOT was associated with increased rates of
TB treatment success compared to unobserved therapy, although the results for treatment
completion and relapse were inconclusive [26]. Mechanisms have, however, been suggested to
prevent a move away from clinic contact affecting treatment completion, including
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appointment reminders for regular defaulters and education for patients on treatment and
side effects [11]. For less complex cases, clinical assessments could be performed locally by
community health workers, thus reducing the burden of care further [25].
A better understanding of the barriers to BU treatment completion must be developed to
inform changes in the management and delivery of care for BU. The extent to which both
ongoing barriers in access to treatment and the introduction of the fully oral treatment have
impacted treatment completion is not well understood. The aim of this study was to review the
BU treatment completion rates in the Ashanti and Central Regions, Ghana, to explore factors
associated with reduced treatment completion and assess the impact of the new oral treatment
regimen on treatment completion.
Methods
We conducted a retrospective study using data extracted from the standard WHO BU treat-
ment forms (BU01 forms [27]). We included patients diagnosed between 1 January 2006 and
31 December 2018 in four clinics across the Ashanti Region (Agogo, Nkawie and Tepa clinics)
and Central Region (Dunkwa clinic), which are estimated to have the highest prevalence of BU
in Ghana [28]. Demographic and treatment information was supplemented by records from
the WHO Buruli Ulcer Trial, which recruited patients between 2013 and 2017 [16]), where
available.
All BU patients for whom clinical notes were available were included if treatment com-
menced and was either completed or assumed permanently defaulted (i.e. with either the
patient documented as defaulted on the BU01 form or no further treatment doses recorded)
within this window. Patients enrolled in the TOP trial (2007–2008) where a shorter, and there-
fore non-comparable, treatment regimen was studied, were excluded (n = 47).
Data extraction was undertaken at the Kumasi Centre for Collaborative Research in Tropi-
cal Medicine (KCCR) in Kumasi, which has established links with the four BU clinics. Usual
practice is for three sets of BU01 forms to be filled in per patient, with one each for the patient,
the health facility and the KCCR team. Where data was missing from the KCCR copy, the rele-
vant treatment centres were visited where possible to assess the health facility version and the
most complete copy used. Discrepancies were resolved by consensus amongst the study team.
Statistical analysis
Data was cleaned in Excel and analysed in STATA 15 (StataCorp 2017, TX, USA). Preliminary
data assessment was performed, including for the degree of missing data. If a variable had
more than 10% of its data missing, the distribution of missing data across the main exposure
categories was examined and disparities acknowledged in the interpretation of results.
Variables with fewer than ten outcomes in a stratum were regrouped where appropriate to
increase stratum numbers for analysis. For the purpose of analysis, occupation was classified
as farmer, pupil or other occupation; lesion location was classified as trunk, upper limb, lower
limb and multiple/other; lesion form was classified as non-ulcer, ulcer and multiple/osteomye-
litis; referral route was classified as village health volunteer, health worker and other and year
of diagnosis was classified as 2006–10, 2011–14 and 2015–18. Univariable analysis was con-
ducted, controlling for age and sex, which were considered a priori confounders. Variables
with some evidence of association with treatment completion (p< 0.1) were included in the
multivariable regression model, alongside the main explanatory variables ‘distance to clinic’
and ‘treatment regimen’. Lesion category, lesion form and duration of lesion were considered
to be proxies for lesion severity and likely to stem from treatment accessibility. They were
therefore thought to be on the causal pathway and so were not included in the multivariable
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regression model. Year of diagnosis was considered to be collinear with treatment regimen,
with CR8 provided partially during 2013–16 as part of a WHO trial [16] and fully from 2017
onwards and was therefore excluded. The model was assessed for clustering at the facility level;
as there was no evidence of clustering, a random effects model was not fitted.
Variable determination
Distance to clinic was used as an indirect measure of treatment accessibility. Village locations
were determined in ArcGIS using the Ghana Settlements data obtained from the Humanitar-
ian Data Exchange [29]. Villages documented on BU01 forms were identified as those located
closest to the clinic attended with the same name. If more than one potential location was
identified and the correct one could not be determined by local staff, the village was not plot-
ted. The point distance between the village and clinic attended was measured.
Treatment completion was determined in patients who had taken at least 95% of the full 56
days of treatment (i.e. with both antibiotics taken each day). A patient was considered to have
not adequately completed treatment if they did not complete the course within a 70-day
period, as such patients were expected to restart treatment.
Ethics
The project was conducted as part of the research Pathogenesis and Management of M. Ulcer-
ans Disease (Buruli ulcer), which was approved by the Committee on Human Research and
Publication Ethics of the School of Medical Sciences at the Kwame Nkrumah University of Sci-
ence and Technology (Ref. CHRPE/AP/245/19).
Results
A total of 978 BU patients were seen across the four clinics between 1 January 2006 and 31
December 2018. We excluded 47 patients who participated in the TOP trial, leaving 931 in the
analysis (NB the denominator used throughout will vary due to missing data). There were
three repeat presentations amongst the 931 patients. Overall 480 (52%) of the patients with sex
documented were female and the median age was 14 (IQR 8–30). The majority of patients
attended clinics in Agogo (49.1%) and Tepa (39.7%) (Table 1). Data on treatment completion
was available for 676 patients (72.6%).
We found evidence that both lesion form and lesion category differed by distance to clinic.
Patients with ulcerated lesions and multiple lesions or osteomyelitis were more likely to live
over 20km from the clinic compared to patients with non-ulcer lesion forms (OR 2.6, 95% CI
1.8–3.7, p< 0.001 and OR 4.2, 95% CI 1.7–10.4, p = 0.002 respectively), whilst patients with
category II and III lesions were also more likely to live over 20km from the clinic compared to
patients with category I lesions (OR 2.3, 95% CI 1.5–3.4, p< 0.001 and OR 3.1, 95% CI 1.2–
5.0, p< 0.001 respectively). We also found that patient referral pattern varied by lesion form.
Patients referred by health workers were more likely to have more advanced lesion forms
(ulcerated lesions and multiple lesions or osteomyelitis) compared to patients referred by vil-
lage health volunteers (OR 3.0, 95% CI 2.2–4.1, p< 0.001) (Table 1).
Data on the distance to clinic was available for 562 (60.4%) patients. For these patients, the
distance ranged from 0km (i.e. living in the village of the clinic) to 191.3km; the median dis-
tance to clinic was 17km (IQR 6.2–24.2km). There was no evidence of association between dis-
tance to the clinic and treatment completion with 79.8% of individuals living within 10km
completing treatment compared to 87.4% of those living 10-20km from clinic (OR 1.51, 95%
CI 0.72–3.14) and 87.3% of those living more than 20km from clinic (OR 1.36, 95% CI 0.66–
2.83) (Table 2).
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Table 1. Characteristics of the study population (total n = 931�).
Demographic characteristic Details
Male sex, n (%) 441 (47.9)
Missing data 1.1%
Age, years [median (IRQ)] 14 (8–30)
Missing data 0.8%
Occupation, n (%)
Pupil 510 (59.0)
Farmer 274 (31.7)
Othera 80 (9.3)
Missing data 7.2%
Year of diagnosis, n (%)
2006–10 301 (32.5)
2011–14 453 (48.9)
2015–18 173 (18.7)
Missing data 0.4%
Clinic attended, n (%)
Agogo 457 (49.1)
Dunkwa 58 (6.2)
Nkawie 46 (4.9)
Tepa 370 (39.7)
Missing data 0%
Distance to clinic, km [median (IQR)] 17 (6.2–24.2)
Missing data (total) 39.6%
Missing data (by regimen) SR8 38%, CR8
44%
Referral route, n (%)
[OR for having advanced lesion�� vs village health worker]
Village health volunteer 294 (34.0)
Health worker 373 (43.2)
[OR 3.0, 95% CI
2.2–4.1,
p < 0.001]
Otherb 197 (22.8)
[OR 2.1, 95% CI
1.4–3.0,
p < 0.001]
Missing data 7.2%
Duration of lesion at diagnosis, weeks [median (range; IQR)] 4 (0.5–1196; 2–8)
Missing data 6.2%
Used traditional treatment, n (%) 271 (31.7)
Missing data 8.2%
Lesion Location, n (%)
Upper limb 349 (38.3)
Lower limb 467 (51.2)
Trunk 54 (5.9)
Multiple/Otherc 42 (4.6)
Missing data 2%
Lesion form at diagnosis, n (%)
[% by distance to clinic; OR for living >20km from clinic vs those with non-ulcer]
(Continued)
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Table 1. (Continued)
Demographic characteristic Details
Non-ulcer 411 (44.9)
[0- km: 35, 10-
km: 41, 20+ km:
24]
Ulcer 496 (51.3)
[0- km: 21, 10-
km: 34, 20+ km:
45; OR 2.6, 95%
CI 1.8–3.7, p
<0.001]
Multiple/osteomyelitis 43 (3.8)
[0- km: 10, 10-
km: 33, 20+ km:
57; OR 4.2, 95%
CI 1.7–10.4,
p = 0.002]
Missing data 1.7%
Lesion category at diagnosis, n (%)
[% by distance to clinic; OR for living >20km from clinic vs those with category I lesion]
I 420 (47.1)
[0- km: 31, 10-
km: 44, 20+ km:
24]
II 279 (31.3)
[0- km: 23, 10-
km: 35, 20+ km:
42; OR 2.3, 95%
CI 1.5–3.4, p
<0.001]
III 192 (21.3)
[0- km: 23, 10-
km: 27, 20+ km:
50; OR 3.1, 95%
CI 1.2–5.0, p
<0.001]
Missing data 4.3%
Treatment regimen taken, n (%)
SR8 698 (78.3)
CR8 194 (21.8)
Missing data 4.2%
Completed treatment, n (%) 569 (84.4)
Missing data (total) 27.4%
Missing data (by regimen) SR8 32%, CR8 6%
Missing data (by distance) 0- km 35%, 10-
km 28%, 20+ km
25%
�Total n = 931, but all variable results are based on the data available for that variable
�� ulcer, multiple lesions or osteomyelitis
a: Other occupation includes hairdresser, trader, miner, driver, tailor, teacher, unemployed, retired and all single-
count occupations
b: Other referral route includes family member, former patient and self
c: other location includes eye, head and neck, breast, perineum and genitalia.
https://doi.org/10.1371/journal.pntd.0008369.t001
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Table 2. Baseline variable distributions and their univariable associations with treatment completion, controlling for forced variables age and sex (total n = 931�).
Variable No. (%) patients No. (%��) completing treatment Univariate OR (95% CI) P value���
Sex (n = 921)
Female
Male
480 (52.1) 295 (84.5) 1 0.0582
441 (47.9) 270 (84.4) 0.88 (0.57–1.35)
Age group (years) (n = 924)
0-
5-
10-
20-
30-
40-
50-
60+
81 (8.8) 48 (87.3) 1 0.0582
200 (21.7) 126 (91.3) 1.56 (0.57–4.19)
286 (31.0) 187 (86.6) 0.98 (0.40–2.39)
114 (12.3) 61 (82.4) 0.67 (0.25–1.82)
94 (10.2) 55 (79.7) 0.56 (0.21–1.52)
60 (6.5) 36 (78.3) 0.51 (0.18–1.48)
42 (4.6) 27 (77.1) 0.48 (0.16–1.48)
47 (5.1) 26 (72.2) 0.38 (0.13–1.12)
Distance to clinic (km) (n = 562)
0-
10-
20+
153 (27.2) 79 (79.8) 1
210 (37.4) 132 (87.4) 1.51 (0.72–3.14)
199 (35.4) 130 (87.3) 1.36 (0.66–2.83) 0.0754
Treatment regimen (n = 892)
SR8
CR8
698 (78.3) 385 (80.7) 1
194 (21.8) 170 (93.4) 4.27 (2.20–8.31) <0.0001
Clinic attended (n = 931)
Agogo
Dunkwa
Nkawie
Tepa
457 (49.1) 238 (84.4) 1 0.1599
58 (6.2) 39 (86.7) 1.28 (0.50–3.26)
46 (4.9) 29 (85.3) 1.28 (0.46–3.56)
370 (39.7) 263 (84.0) 1.09 (0.68–1.72)
Occupation (n = 864)
Farmer
Pupil
Othera
274 (31.7) 148 (74.4) 1 0.0054
510 (59.0) 331 (88.7) 5.14 (1.78–14.89)
80 (9.3) 52 (85.3) 2.10 (0.95–4.64)
Traditional treatment use (n = 855)
No
Yes
584 (68.3) 343 (82.3) 1
271 (31.7) 173 (87.4) 1.50 (0.91–2.48) 0.0607
Lesion location (912)
Upper limb
Lower limb
Trunk
Multiple/Otherb
349 (38.3) 211 (84.7) 1 0.1129
467 (51.2) 285 (83.3) 1.08 (0.68–1.71)
54 (5.9) 35 (85.4) 0.90 (0.35–2.36)
42 (4.6) 31 (93.9) 2.51 (0.57–11.06)
Referral route (n = 864)
Health worker
Village health volunteer
Otherc
373 (43.2) 252 (83.4) 1 0.0444
294 (34.0) 145 (82.4) 0.85 (0.51–1.41)
197 (22.8) 131 (87.3) 1.31 (0.73–2.35)
Duration of lesion (weeks) (n = 873)
0-
2-
3-
4-
5-
12-
52+
75 (8.6) 36 (83.7) 1 0.2589
146 (16.7) 78 (83.9) 1.19 (0.43–3.27)
120 (13.8) 79 (83.2) 1.03 (0.38–2.78)
193 (22.1) 126 (86.9) 1.54 (0.59–4.09)
162 (18.6) 102 (80.3) 0.95 (0.37–2.44)
138 (15.8) 84 (84.0) 1.33 (0.49–3.59)
39 (4.5) 23 (79.3) 1.31 (0.36–4.79)
Year of diagnosis (n = 927)
(Continued)
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Table 2. (Continued)
Variable No. (%) patients No. (%��) completing treatment Univariate OR (95% CI) P value���
2006–2010
2011–2014
2015–2018
301 (32.5) 109 (87.9) 1
453 (48.9) 320 (83.3) 0.62 (0.33–1.18)
173 (18.7) 138 (84.7) 0.87 (0.42–1.81) 0.0467
Lesion form (n = 915)
Ulcer
Non-ulcer
Multiple/osteomyelitis
496 (51.3) 291 (83.9) 1 0.1139
411 (44.9) 249 (85.6) 0.99 (0.63–1.58)
43 (3.8) 23 (76.7) 0.65 (0.25–1.73)
Lesion category (n = 891)
I
II
III
420 (47.1) 236 (85.5) 1 0.0911
279 (31.3) 189 (84.0) 0.85 (0.51–1.41)
192 (21.3) 119 (83.8) 0.96 (0.54–1.71)
�Total n = 931, but all variable results are based on the data available for that variable
��Denominator differs from the baseline data for that variable due to missing data for treatment completion.
���From LRT for association between variable and treatment completion, controlling for age and sex (age and sex are controlled for each other).
a: ‘Other’ occupation includes hairdresser, trader, miner, driver, tailor, teacher, unemployed, retired and all single-count occupations
b: ‘other location’ includes eye, head and neck, breast, perineum and genitalia
c: ‘Other referral route’ includes family member, former patient and self.
https://doi.org/10.1371/journal.pntd.0008369.t002
Table 3. Basic and fully adjusted multivariable regression models for the association between exposure variables and treatment completion (including ‘distance to
clinic’).
Variable Basic model Adjusted� OR (95% CI) n = 363 P value�� Full model
Adjusted� OR (95% CI) n = 325
P value��
Sex
Female
Male
1 1
1.03 (0.56–1.89) 0.924 0.85 (0.44–1.64) 0.621
Age (years)
Per 1-year increase 0.98 (0.96–0.99) 0.004
1.00 (0.98–1.03) 0.773
Distance to clinic (km)
0-
10-
20+
1 1
1.68 (0.79–3.54) 0.176 1.94 (0.86–4.38) 0.111
1.64 (0.78–3.44) 0.189 1.25 (0.57–2.76) 0.576
Treatment regimen
SR8
CR8
1 1
2.98 (1.20–7.40) 0.018 2.98 (1.18–7.54) 0.021
Referral route
Health worker
Village health volunteer
Other
1
0.75 (0.36–1.59) 0.455
1.08 (0.46–2.50) 0.862
Occupation
Farmer 1
Pupil 3.97 (1.40–11.24) 0.010
Other 1.80 (0.65–5.04) 0.261
Traditional treatment use
No 1
Yes 2.34 (1.03–5.35) 0.043
�Adjusted for all other variables in the column
��P values are based on the Wald test
https://doi.org/10.1371/journal.pntd.0008369.t003
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Across the study period 194 (21.8%) patients took CR8. Compared to the previous SR8 regi-
men, use of the CR8 regimen was strongly associated with treatment completion, with 93.4%
(170/182) of those taking CR8 completing treatment compared to 80.7% (385/477) of those
taking SR8 (OR 4.27, 95% CI 2.20–8.31, p<0.0001). We also found that occupation was associ-
ated with treatment completion, with pupils being more likely to complete treatment than
farmers (OR 5.14, 95% CI 1.78–14.89, p = 0.005) (Table 2).
Multivariable logistic regression
In the multivariable regression model (Table 3) there remained no statistically significant asso-
ciation between distance to clinic and treatment completion (10km+ OR 1.94, 95% CI 0.86–
4.38, p = 0.111; 20km+ OR 1.25, 95% CI 0.57–2.76, p = 0.576). Due to the degree of missing
data for this variable, the model appeared to suffer from sparse data and so a reduced model
excluding distance to clinic was produced (Table 4). In both the model including distance
(Table 3) and the reduced model, the CR8 treatment regimen was associated with higher treat-
ment completion compared to use of the SR8 regimen (OR 4.1, 95% CI 2.03–8.27, p<0.001)
(Table 4). There was no evidence of statistically significant associations between age, sex, refer-
ral route, use of traditional treatment or occupation and treatment completion in the final
multivariable regression model.
Discussion
In our current study we found the rate of treatment completion was 84.4% across four major
BU clinics in the Ashanti and Central Regions between 2006 and 2018. The rate of treatment
Table 4. Basic and fully adjusted reduced multivariable regression models for the association between exposure variables and treatment completion (excluding ‘dis-
tance to clinic’).
Variable Basic model
Adjusted� OR (95% CI) n = 619
P value�� Full model
Adjusted� OR (95% CI) n = 554 P value��
Sex
Female
Male
1 1
0.87 (0.55–1.36) 0.537 0.89 (0.55–1.44) 0.641
Age (years)
Per 1-year increase 0.97 (0.96–0.99) <0.001 0.98 (0.96–1.00) 0.098
Treatment regimen
SR8
CR8
1 1
3.81 (1.94–7.51) <0.001 4.10 (2.03–8.27) <0.001
Referral route
Health worker
Village health volunteer
Other
1
0.87 (0.51–1.50) 0.623
1.38 (0.73–2.61) 0.321
Occupation
Farmer 1
Pupil 1.83 (0.83–4.03) 0.133
Other 2.05 (0.87–4.82) 0.102
Traditional treatment use
No 1
Yes 1.38 (0.81–2.36) 0.238
�Adjusted for all other variables in the column
��P values are based on the Wald test
https://doi.org/10.1371/journal.pntd.0008369.t004
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completion documented was much higher than the 46% found by Klis et al in the same region
in 2014 [10] though there is still scope for improvement. We found clear evidence that the new
fully oral CR8 regimen was associated with improved treatment completion. This is the first
study to demonstrate that recent changes to recommend CR8 as first line treatment [1] might
translate into improved treatment completion rates. Patients receiving fully oral therapy are
able to self-administer treatment under the supervision of Community Based Surveillance Vol-
unteers (CBSV), who are present within each community in a Health District. CBSVs receive
regular training by the health service to support patients by making home visits, monitoring
pill counts and providing a communication link to the health service should any issues arise
[20]. The improved completion rates seen may reflect both the less demanding nature of CR8
on patients’ time and resources and the improved tolerability of CR8 compared to daily injec-
tions as part of the SR8 regimen, whilst the use of CBSVs to monitor care in the community
allows ongoing monitoring and adherence support, reducing the risk that individuals may
default from care if they do not need to regularly attend a health facility [10]. As we do not
have detailed data on reasons for non-completion, we are not able to be certain if tolerability,
provision of care in the community or other factors are the major drivers of improved compli-
ance seen with the CR8 regimen. With a higher proportion of missing data for treatment com-
pletion in those who took SR8, it is possible that this effect could be greater than indicated by
our analysis.
We did not find any evidence that distance to clinic was associated with treatment comple-
tion. Other studies have clearly documented the impact that indirect costs, in particular those
related to transportation may have on treatment seeking and adherence [10]. Whilst it would
be anticipated that greater distances are associated with increasing barriers to care our measure
of distance to clinic is almost certainly an imperfect measure as it cannot fully capture varia-
tions in the time needed for and cost of accessing care. We did note important associations
with lesion type and category and distance to clinic. In particular, increasing distance from
clinic was associated with presenting with ulcerated lesions, osteomyelitis and category II and
III lesions. These findings support suggestions that patients may delay seeking appropriate
care for BU due to direct and indirect costs of transport to and accessibility of BU clinics
[17,18]. The increasing severity of lesions amongst patients living further away from clinics
might also reflect less awareness of the condition in these communities or less strong active
case finding programmes in these settings. As more severe forms are likely to be associated
with worse outcomes in terms of disability and stigma our data support the need to consider
further decentralisation of care, and in particular access to early identification and treatment
in order to improve rates of early detection of the disease.
The benefits of community-based care have been widely recognised in the management of
other mycobacterial infections with lengthy treatment regimens, such as TB and leprosy. Simi-
lar barriers to diagnosis and treatment have been cited, such as long distances to health facili-
ties and transport and opportunity costs incurred from accessing treatment [30,31].
Community health workers and volunteers have been regarded as key in supporting a model
of care that addresses such issues, undertaking a range of roles including community outreach
to increase early detection of disease, direct observation of treatment and psychosocial support
[30,32] and consideration should be given to their use in the management of BU. New portable
diagnostic tests may help facilitate this [33] whilst the introduction of the CR8 regimen should
further facilitate fully decentralised and fully community-based care.
Our study has a number of limitations. Most notably we relied on routine clinical records
and data was therefore missing for some variables. Whilst we attempted to minimise this by
utilising both the records held at KCCR and the primary clinic copy of the BU01 form, missing
data remains a challenge. Secondly, as already outlined there are a number of issues with the
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measurement of ‘distance to care’ [34]. Village names on BU01 forms could not always be
matched with the spatial data [29] due to gaps in the spatial dataset, multiple villages within
the region sharing the same name and the legibility of handwritten clinical notes. There was
also difficulty with consistency in defining distance to care [34], as documented village of resi-
dence may not always reflect where the patient travelled from during treatment, for example
with some staying with relatives closer to the clinic or hospitalised during treatment. Finally,
point distance measurements do not fully consider clinic accessibility, not capturing the full
length of the route, availability of public transport, the road conditions and the time and cost
necessary for the journey. Despite this limitation we found clear evidence that increasing dis-
tance is associated with later presentation highlighting the need for ongoing efforts to improve
early access to diagnosis.
There are also potential differences in the recording of treatment completion between regi-
mens. Completed treatment was documented with differing frequency for SR8, measured
through direct daily observation, compared to CR8 which was measured by fortnightly blister
pack counts. Whilst this may have introduced some potential for bias, we believe it is unlikely
to undermine the strong and highly plausible association seen between regimens and treat-
ment completion. Finally, we had limited information available on potential confounders such
as socioeconomic status. Future prospective studies, measuring both socio-economic variables
and more accurately assessing access to care would greatly enhance our understanding of how
to optimise BU treatment seeking behaviours and treatment completion.
Our study demonstrates that BU treatment completion in the Ashanti and Central Regions,
Ghana are substantially higher with the now recommended oral CR8 regimen compared to
the previous SR8 regimen. This finding, which likely reflects the benefits of both treatment tol-
erability and accessibility, are supportive of the notion of further decentralisation of BU care
towards a fully community-based model. Further research is needed, to ascertain the most
appropriate means of further decentralising care, for example self, peer or CBSV delivered
wound care. We found evidence that distance to health facilities continues to be associated
with more severe forms of BU. Any decentralised system must also therefore continue to sup-
port community engagement and active outreach to identify cases early, when they can be
most easily managed in the community and when long term disability can be avoided. Ideally
such a strategy would reduce costs both to patients, by removing costs of seeking care and to
health systems, by detecting cases early when care and its associated costs are lower. The com-
bination of point-of-care tests and oral treatment regimens makes such a strategy feasible, but
investment and research will be needed to make it a reality.
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